Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome
NCT01165996 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25
Last updated 2019-03-04
Summary
RATIONALE: Decitabine may help myelodysplastic cells become more like normal stem cells. PURPOSE: This clinical trial studies differentiation therapy with decitabine in treating patients with myelodysplastic syndrome.
Conditions
- Chronic Myelomonocytic Leukemia
- de Novo Myelodysplastic Syndromes
- Myelodysplastic Syndromes
- Refractory Anemia
- Refractory Anemia With Excess Blasts
- Refractory Anemia With Ringed Sideroblasts
- Refractory Cytopenia With Multilineage Dysplasia
- Thrombocytopenia
Interventions
- OTHER
-
flow cytometry
Correlative studies
- OTHER
-
DNA methylation analysis
Correlative studies
- OTHER
-
cytogenetic analysis
Correlative studies
- DRUG
-
decitabine
Given subcutaneously
- GENETIC
-
microarray analysis
Correlative studies
- GENETIC
-
gene expression analysis
Correlative studies
- OTHER
-
pharmacological study
Correlative studies
- GENETIC
-
polymorphism analysis
Correlative studies
Sponsors & Collaborators
-
Case Comprehensive Cancer Center
lead OTHER
Principal Investigators
-
Yogen Saunthararajah · Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
-
Brenda Cooper, MD · Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-07-31
- Primary Completion
- 2011-12-31
- Completion
- 2012-08-31
Countries
- United States
Study Locations
More Related Trials
-
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
NCT06847867 ·Status: RECRUITING ·Phase: PHASE2
-
Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
NCT00049582 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome
NCT02013102 ·Status: UNKNOWN ·Phase: PHASE4
-
Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
NCT00492401 ·Status: COMPLETED ·Phase: PHASE2
-
Decitabine in Treating Patients With Myelofibrosis
NCT00095784 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
NCT00941109 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
NCT05568225 ·Status: TERMINATED ·Phase: PHASE2
-
Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)
NCT00903760 ·Status: COMPLETED ·Phase: PHASE2
-
An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome
NCT01751867 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
NCT00619099 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)
NCT02779569 ·Status: UNKNOWN ·Phase: NA
-
Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis
NCT00630994 ·Status: TERMINATED ·Phase: PHASE2
-
Tipifarnib in Treating Patients With Myelodysplastic Syndromes
NCT00005845 ·Status: COMPLETED ·Phase: PHASE1
-
CPX-351 Therapy for MDS After Hypomethylating Agent Failure
NCT03957876 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome
NCT02363491 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes
NCT00828802 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome
NCT00796003 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes
NCT00458159 ·Status: TERMINATED ·Phase: PHASE1
-
Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)
NCT00067808 ·Status: COMPLETED ·Phase: PHASE2
-
Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)
NCT01098084 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)
NCT01822691 ·Status: COMPLETED ·Phase: PHASE2
-
Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome
NCT00003123 ·Status: UNKNOWN ·Phase: PHASE2
-
An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)
NCT01026376 ·Status: NO_LONGER_AVAILABLE
-
Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure
NCT00113321 ·Status: TERMINATED ·Phase: PHASE2
-
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
NCT02093429 ·Status: TERMINATED ·Phase: PHASE1/PHASE2